Restricted accessResearch articleFirst published online 2013-03
Additive Effects of 5-HTTLPR (Serotonin Transporter) and Tryptophan Hydroxylase 2 G-703T Gene Polymorphisms on the Clinical Response to Citalopram among Children and Adolescents with Depression and Anxiety Disorders
The purpose of this study was to evaluate the association between polymorphisms in two serotonin pathway genes and the clinical response to citalopram among children and adolescents with depression and/or anxiety disorders.
Methods:
Eighty-three children and adolescents with depression and/or anxiety disorders were treated with citalopram for 8 weeks. We assessed the association between the response to citalopram and polymorphisms in the tryptophan hydroxylase-2 (TPH2) and the serotonin transporter gene. The polymorphisms included single nucleotide polymorphisms (SNPs) in the transcriptional control region (G-703T) of the TPH2 gene and the serotonin transporter gene-linked promoter region (5-HTTLPR).
Results:
Fifty patients of the 83 (60.2%) achieved satisfactory response (Clinical Global Impressions - Improvement ≤2). We observed an additive effect of the two genes on the clinical response to citalopram. Patients carrying the combination of TPH2 −703G and the 5-HTTLPR L alleles were the most likely to respond (80%). In contrast, patients carrying the combination of TPH2 −703T and the 5-HTTLPR S alleles were least likely to respond (31%). The other patients (with −703G/5-HTTLPR S and −703T/5-HTTLPR L alleles) showed intermediate response (67%).
Conclusions:
This finding suggests that 5-HTTLPR and TPH2 genes may act in concert to modulate the clinical response to citalopram among children and adolescents with depression and/or anxiety disorders.
Get full access to this article
View all access options for this article.
References
1.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4thText Revision. Washington, DC: American Psychiatric Association, 2000.
2.
Anonymous. Practice parameters for the assessment and treatment of children and adolescents with depressive disorders. J Am Acad Child Adolesc Psychiatry, 46:1503–1526. 2007.
3.
BrownSM, PeetE, ManuckSB, WilliamsonDE, DahlRE, FerrellRE, HaririAR. A regulatory variant of the human tryptophan hydroxylase-2 gene biases amygdale reactivity. Mol Psychiatry, 10:884–888. 2005.
4.
CanliT, CongdonE, GutknechtL, ConstableRT, LeschKP. Amygdala responsiveness is modulated by tryptophan hydroxylase-2 gene variation. J Neural Transm, 112:1479–1485. 2005.
5.
CanliT, CongdonE, Todd ConstableR, LeschKP. Additive effects of serotonin transporter and tryptophan hydroxylase-2 gene variation on neural correlates of affective processing. Biol Psychol, 79:118–125. 2008.
6.
CanliT, LeschKP. Long story short: The serotonin transporter in emotion regulation and social cognition. Nat Neurosci, 10:1103–1109. 2007.
7.
ChenGL, VallenderEJ, MillerGM. Functional characterization of the human TPH2 5' regulatory region: Untranslated region and polymorphisms modulate gene expression in vitro. Hum Genet, 122:645–657. 2008.
8.
CostelloEJ, EggerHL, AngoldA. The developmental epidemiology of anxiety disorders: Phenomenology, prevalence, and comorbidity. Child Adolesc Psychiatr Clin N Am, 14:631–648. 2005.
9.
CostelloEJ, MustilloS, ErkanliA, KeelerG, AngoldA. Prevalence and development of psychiatric disorders in childhood and adolescence. Arch Gen Psychiatry, 60:837–844. 2003.
10.
CostelloEJ, PineDS, HammenC, MarchJS, PlotskyPM, WeissmanMM, BiedermanJ, GoldsmithHH, KaufmanJ, LewinsohnPM, HellanderM, HoagwoodK, KoretzDS, NelsonCA, LeckmanJF. Development and natural history of mood disorders. Biol Psychiatry, 52:529–542. 2002.
11.
CrisafulliC, FabbriC, PorcelliS, DragoA, SpinaE, De RonchiD, SerrettiA. Pharmacogenetics of antidepressants. Front Pharmacol, 2:1–21. 2011.
12.
EsbjørnBH, HoeyerM, DyrborgJ, LethI, KendallPC. Prevalence and co-morbidity among anxiety disorders in a national cohort of psychiatrically referred children and adolescents. J Anxiety Disord, 24:866–872. 2010.
13.
FrischA, FinkelB, MichaelovskyE, SigalM, LaorN, WeizmanR. A rare short allele of the serotonin transporter promoter region (5-HTTLPR) found in an aggressive schizophrenic patient of Jewish Libyan origin. Psychiatr Genet, 10:179–183. 2000.
14.
FurmarkT, HenningssonS, AppelL, AhsF, LinnmanC, PissiotaA, FariaV, OrelandL, BaniM, PichEM, ErikssonE, FredriksonM. Genotype over-diagnosis in amygdala responsiveness: affective processing in social anxiety disorder. J Psychiatry Neurosci, 34:30–40. 2009.
15.
HerrmannMJ, HuterT, MüllerF, MühlbergerA, PauliP, ReifA, RennerT, CanliT, FallgatterAJ, LeschKP. Additive effects of serotonin transporter and tryptophan hydroxylase-2 gene variation on emotional processing. Cereb Cortex, 17:1160–1163. 2007.
16.
HuXZ, RushAJ, CharneyD, WilsonAF, SorantAJ, PapanicolaouGJ, FavaM, TrivediMH, WisniewskiSR, LajeG, PaddockS, McMahonFJ, ManjiH, LipskyRH. Association between a functional serotonin transporter promoter polymorphism and citalopram treatment in adult outpatients with major depression. Arch Gen Psychiatry, 64:783–792. 2007.
17.
IpserJC, SteinDJ, HawkridgeS, HoppeL. Pharmacotherapy for anxiety disorders in children, adolescents. Cochrane Database Syst Rev., 3:CD005170. 2009.
18.
KennardBD, SilvaSG, TonevS, RohdeP, HughesJL, VitielloB, KratochvilCJ, CurryJF, EmslieGJ, ReineckeM, MarchJ. Remission and recovery in the Treatment for Adolescents with Depression Study (TADS): Acute and long-term outcomes. J Am Acad Child Adolesc Psychiatry, 48:186–195. 2009.
19.
KennardB, SilvaS, VitielloB, CurryJ, KratochvilC, SimonsA, HughesJ, FeenyN, WellerE, SweeneyM, ReineckeM, PathakS, GinsburgG, EmslieG, MarchJ. TADS Team. Remission and residual symptoms after short-term treatment in the Treatment of Adolescents with Depression Study (TADS)J Am Acad Child Adolesc Psychiatry, 45:1404–1411. 2006.
20.
KesslerRC, AvenevoliS, Ries MerikangasK. Mood disorders in children and adolescents: An epidemiologic perspective. Biol Psychiatry., 49:1002–1014. 2001.
21.
KesslerRC, BerglundP, DemlerO, JinR, MerikangasKR, WaltersEE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry, 62:593–602. 2005.
22.
KraftJB, SlagerSL, McGrathPJ, HamiltonSP. Sequence analysis of the serotonin transporter and associations with antidepressant response. Biol Psychiatry, 58:374–381. 2005.
23.
KronenbergS, ApterA, BrentD, SchirmanS, MelhemN, PickN, GothelfD, CarmelM, FrischA, WeizmanA. Serotonin transporter polymorphism (5-HTTLPR) and citalopram effectiveness and side effects in children with depression and/or anxiety disorders. J Child Adolesc Psychopharmacol, 17:741–750. 2007.
24.
LeschKP. Variation of serotonergic gene expression: Neurodevelopment and the complexity of response to psychopharmacologic drugs. Eur Neuropsychopharmacol, 11:457–474. 2001.
25.
LeschKP, BengelD, HeilsA, SabolSZ, GreenbergBD, PetriS, BenjaminJ, MüllerCR, HamerDH, MurphyDL. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science, 274:1527–1531. 1996.
26.
LeonardoED, HenR. Anxiety as a developmental disorder. Neuropsychopharmacology, 33:134–140. 2008.
27.
MarchJ, SilvaS, PetryckiS, CurryJ, WellsK, FairbankJ, BurnsB, DominoM, McNultyS, VitielloB, SevereJ. Treatment for Adolescents With Depression Study(TADS) Team. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial. JAMA, 18:807–820. 2004.
28.
MaronE, TammisteA, KallassaluK, EllerT, VasarV, NuttDJ, MetspaluA. Serotonin transporter promoter region polymorphisms do not influence treatment response to escitalopram in patients with major depression. Eur Neuropsychopharmacol, 19:451–456. 2009.
29.
MrazekDA, RushAJ, BiernackaJM, O'KaneDJ, CunninghamJM, WiebenED, SchaidDJ, DrewsMS, CoursonVL, SnyderKA, BlackJL3rd, WeinshilboumRM. SLC6A4 variation, citalopram response. Am J Med Genet B Neuropsychiatr Genet, 150B:341–351. 2009.
30.
NakamuraM, UenoS, SanoA, TanabeH. The human serotonin transporter gene linked polymorphism (5-HTTLPR) shows ten novel allelic variants. Mol Psychiatry, 5:32–38. 2000.
31.
PorcelliS, FabbriC, SerrettiA. Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with antidepressant efficacy. Eur Neuropsychopharmacol, 22:239–258. 2012.
32.
Pediatric OCD Treatment Study (POTS) Team:. Cognitive-behavior therapy, sertraline, and their combination for children and adolescents with obsessive-compulsive disorder: The Pediatric OCD Treatment Study (POTS) randomized controlled trial. JAMA, 292:1969–1976. 2004.
33.
RyanND, BirmaherB, PerelJM, DahlRE, MeyerV, al-ShabboutM, IyengarS, Puig–AntichJ. Neuroendocrine response to L-5-hydroxytryptophan challenge in prepubertal major depression. Depressed vs normal children. Arch Gen Psychiatry, 49:843–851. 1992.
34.
ScheuchK, LautenschlagerM, GrohmannM, StahlbergS, KirchheinerJ, ZillP, HeinzA, WaltherDJ, PrillerJ. Characterization of a functional promoter polymorphism of the human tryptophan hydroxylase 2 gene in serotonergic raphe neurons. Biol Psychiatry, 62:1288–1294. 2007.
35.
SchirmanS, KronenbergS, ApterA, BrentD, MelhemN, PickN, CarmelM, FrischA, WeizmanA, GothelfD. Effectiveness and tolerability of citalopram for the treatment of depression and anxiety disorders in children and adolescents: an open-label study. J Neural Transm, 117:139–45. 2010.
36.
SerrettiA, KatoM, De RonchiD, KinoshitaT. Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients. Mol Psychiatry, 12:247–257. 2007.
37.
StoltenbergSF, NagP. Description and validation of a dynamical systems model of presynaptic serotonin function: genetic variation, brain activation and impulsivity. Behav Genet, 40:262–279. 2010.
38.
VitielloB. Treatment of adolescent depression: what we have come to know. Depress Anxiety, 26:393–395. 2009.
39.
WagnerKD, BerardR, SteinMB, WetherholdE, CarpenterDJ, PereraP, GeeM, DavyK, MachinA. A multicenter, randomized, double-blind, placebo-controlled trial of paroxetine in children and adolescents with social anxiety disorder. Arch Gen Psychiatry, 61:1153–1162. 2004.
40.
WalkupJT, AlbanoAM, PiacentiniJ, BirmaherB, ComptonSN, SherrillJT, GinsburgGS, RynnMA, McCrackenJ, WaslickB, IyengarS, MarchJS, KendallPC. Cognitive behavioral therapy, sertraline, or a combination in childhood anxiety. N Engl J Med, 359:2753–2766. 2008.
WeizmanA, WeizmanR. Serotonin transporter polymorphism and response to SSRIs in major depression and relevance to anxiety disorders and substance abuse. Pharmacogenomics, 1:335–341. 2000.
